Aberrant Crypt Foci: The Case for Inclusion as a Biomarker for Colon Cancer

Cancers

Michael J. Wargovich¹  Vondina R. Brown² 

[1] Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Hollings Cancer Center, Medical University of South Carolina, Charleston SC 29425 USA;

关键词: aberrant crypt foci;    biomarker;    colon cancer;    chemoprevention;   

DOI  :  10.3390/cancers2031705

来源: mdpi

【 摘 要 】

Aberrant crypt foci (ACF) are one of the earliest histopathological manifestations of colon cancer. In this review, we critically present the molecular, cellular, histopathological, and chemopreventive evidence that ACF are relevant biomarkers for colon cancer. The laboratory and clinical evidence are highly suggestive that ACF are in the pathway leading to colon cancer, but not all ACF will do so. The possible fate and outcome of ACF in the progression toward colon cancer may be dependent on a number of features that define their predictive power for the prevention or progression of cancer.

【 授权许可】

CC BY   
© 2010 by the authors; licensee MDPI, Basel, Switzerland.